BioLift

BioLift

BioLift™, powered by Mosaic Biosciences®, is a scientifically validated biological fertilizer complement that unlocks tied-up nutrients in the soil, amplifies early-season growth and maximizes a grower’s fertility investment.

BioLift transforms those bound nutrients into plant-available forms to maximize access to nutrition when crops need it most. With reliable, shelf-stable performance – no special handling or storage required – BioLift is a high-value, low maintenance addition that fits seamlessly into existing fertility programs that include UAN and other liquid fertilizers. 

Read more

Product Benefits

  • Has up to 18 months of shelf life in fertilizer and 24 months of shelf life in concentrate, with no special handling required.
  • Blends seamlessly with UAN and other liquid fertilizers.
  • Solubilizes bound nutrients for optimal plant availability. 
  • Enhances root mass and plant vigor. 
  • Accelerates early-season root and shoot development. 
  • Demonstrates improved nutrient uptake for better ROI.

Product Specifications

Active Ingredient:Five unique strains of Plant Growth Promoting Rhizobacteria (PGPR)
Formulation:Water-based formulation blended with UAN
Application:Sidedress and topdress with UAN
Restricted Use:No

The Science

The bioactives in BioLift produce enzymes and organic acids that improve the solubilization of fertilizer into plant-available forms and release bound nutrients. More availability of nutrients can increase nutrient uptake and provide greater root volume to improve overall plant growth and vigor. As a result, yield potential and harvest quality are optimized.

Primary Crops

Corn, Wheat, Cotton, Soybeans

Field trial data

Comparisons between BioLift and grower standard checks resulted in a 5.2 bu/A average yield increase from BioLift in 80% of comparisons over a 3-year period.

The bar graph compares corn yields from two treatments: Control (226.2 bu/A) and BioLift with UAN side dress (231.4 bu/A) for field trials from 2022 to 2024. The data reflects an average across 70 trials.